Navigation Links
Novel publishing approach puts textbook in more hands
Date:10/16/2008

UC San Diego already has a history of pioneering such open access to scientific publications. In 1996, the then San Diego-based editorial board of the Journal of Clinical Investigation made it the first well-known scientific journal to publish all articles free online. Philip E. Bourne, Ph.D., Professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego, founded SciVee, an open-access website that provides community web services and video resources for researchers of all levels to create and share scientific data using compelling new multimedia resources. Dr. Bourne was one of the two featured speakers on Open Access Day, along with Richard Roberts, Ph.D., of New England Biolabs, joint winner of the Nobel Prize in Physiology or Medicine 1993 and a pioneer in supporting taxpayer access to publicly funded research.

The first edition of Essentials of Glycobiology, published in print in 1999, was released online as part of the NCBI Bookshelf in 2003. The content of the second edition of Essentials of Glycobiology has been completely updated and expanded to reflect the new findings and extensive progress in the field of glycobiology that has occurred since the first edition appeared nearly 10 years ago.

"Hundreds of people every week have continued to look at the first edition of Essentials of Glycobiology online," wrote David Lipman, M.D., NCBI Director, in the preface to the new edition. "These readers are geographically dispersed, including from parts of Africa, South America, and Asia. The audience is also educationally dispersed: the book is referenced in Wikipedia, university libraries all over the world list and link to the electronic book, and major Internet search engines index the content."

While the first edition focused primarily on vertebrate glycobiology, the second edition reflects the fact that glycosylation is universal, that all cells in all speciesfrom eubacteria
'/>"/>

Contact: Ingrid Benirschke
benirsch@cshl.edu
619-275-6021
Cold Spring Harbor Laboratory
Source:Eurekalert  

0

GOOD

Page: 1 2 3 4

Related biology news :

1. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
2. Childrens National researchers develop novel anti-tumor vaccine
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Conaway Lab identifies novel mechanism for regulation of gene expression
5. Scientists identify novel inhibitor of human microRNA
6. Using novel tool, UD researchers dig through cell trash and find treasure
7. Novel anti-cancer mechanism found in long-lived rodents
8. Novel fungus helps beetles to digest hard wood
9. GIANT-Coli: A novel method to quicken discovery of gene function
10. Novel structure proteins could play a role in apoptosis
11. Novel approach may protect against heart attack injury
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel publishing approach puts textbook in more hands
Novel publishing approach puts textbook in more hands
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)PHILADELPHIA Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 1HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 1CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 2CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 4Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 1Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 2Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 3Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 4
...ester scientists are to investigate the biological... after Alzheimer,s, thanks to a prestigious 1.9 mi...earch Council. , Frontotemporal lobar degeneratio...rontal and temporal lobes of the brain and are cha...rather than the memory loss associated with Alzhei...
...utions to Identify Individuals for Access to ...ions, WALL, N.J., Sept. 22 BIO-key International...er-based biometric,identification and wireless pub...etwork, is showcasing its fingerprint biometric so... being held at the Moscone Center in San,Francisco...
...A glitch in the ability to move iron around in cel...idosis (ML4) and the suite of symptoms---mental re...ies---that accompany it, new research at the Unive... may be involved in aging and neurodegenerative di...ead author Haoxing Xu, an assistant professor of m...
Other Biology News:£2 million study to reveal workings of dementia genes 2BIO-key(R) International To Exhibit at Oracle OpenWorld 2BIO-key(R) International To Exhibit at Oracle OpenWorld 3BIO-key(R) International To Exhibit at Oracle OpenWorld 4Iron-moving malfunction may underlie neurodegenerative diseases, aging 2Iron-moving malfunction may underlie neurodegenerative diseases, aging 3
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...France, April 23 , - Strong 10.3% Growth in F...the world leader in ophthalmic optics, today,annou...the three months ended,March 31, 2009, representin...f 2008. Excluding the currency effect, growth was ...and early in the year, revenue was down just 1%,li...
...l 22 Hovione held today the opening,ceremony of i...ing site in,Cork. Hovione contracted with Pfizer l...anufacturing Lipitor(R) since 1997. The handover o...ction closed on the 8th; going forward,Hovione wil...e for Pfizer but,will mostly make use of the avail...
...inducted into National Academy of Sciences for gro... WASHINGTON, April 22 Sir Philip Cohen of Scotlan...he U.S. National Academy of Sciences (NAS) during ...8:00 p.m. at the NAS building for his excellence i...of only four Scottish scientists ever inducted int...
Other Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Hovione Opens its New API Plant in Cork 2Hovione Opens its New API Plant in Cork 3United States Recognizes Leading Scottish Scientist for Disease Research 2
... containing a clone of the human Topoisomerase II ... topological state of nucleic acids by passing an ...enerates a separate DNA helix (1,2) . As a result ...enzyme can relax negatively or positively supercoi...
...I catalyzes the template-directed polymerization o...DNA Polymerase I possesses a 3?5 exonuclease activ...rror rate during DNA replication, and also contain...zyme to replace nucleotides in the growing strand ...
...e Klenow Fragment is a genetically engineered Klen...vity has been removed, leaving only the 5 to 3 pol...ctivity makes Exo- Klenow Fragment the enzyme of c...s by the random primed method, and for DNA sequenc...
T7 RNA Polymerase from Invitrogen
Biology Products: